Translation...A hawt woman who gives great blow-jobs as needed. That is the only job description that justifies the salary.
I've applied! Lets not be sexist. I can close an airplane door with the best of them and I'm very good and cleaning up marble surfaces. INVVY Indivior PLC $24.500.50 (+2.08%)
Opiant wins FDA priority review for opioid overdose therapy.... (Indivior Buying Opiant-! Been in the works since Nov.)
Netflix price target raised to $390 from $330 at JPMorgan 07:00 NFLX JPMorgan analyst Doug Anmuth raised the firm's price target on Netflix to $390 from $330 and keeps an Overweight rating on the shares after the company had strong subscriber growth in Q4. Reed Hastings' move to Executive Chairman "does not come as a surprise" and he expects a seamless transition to co-CEOs Ted Sarandos and Greg Peters, said Anmuth, who remains bullish on Netflix shares.
--CCU upgraded to Overweight from Neutral at JPMorgan 07:07 CCU JPMorgan analyst Lucas Ferreira upgraded CCU to Overweight from Neutral with a CLP 6,600 price target. --SLB reports Q4 adjusted EPS 71c, consensus 68c 06:50 SLB
Ralph Lauren upgraded to Overweight from Equal Weight at Barclays 05:59 RL Barclays analyst Adrienne Yih upgraded Ralph Lauren to Overweight from Equal Weight with a price target of $134, up from $101, citing its position as "a best-in-class apparel brand," continued elevation, improvement in the outlook for its European segments and reduced foreign exchange headwinds.
Netflix price target raised to $417 from $366 at Wolfe Research 06:19 NFLX Wolfe Research analyst Peter Supino raised the firm's price target on Netflix to $417 from $366 and keeps an Outperform rating on the shares, arguing that its Q4 results showed its subscriber growth engine "was in need of spark plug, rather than a rebuild." His base case is that Netflix can add 20M subscribers in 2023, which compares to the 13.5M net adds consensus, said Supino, who attributes his increased target to a more favorable subscriber outlook, guidance for 2023 free cash flow of at least $3B, and the company stating that paid sharing will be rolled out more broadly in Q1.
Mirati Therapeutics says FDA clears IND application of MRTX1133 17:01 MRTX Mirati Therapeutics announced the U.S. Food and Drug Administration has cleared the Investigational New Drug application of MRTX1133, a potential first-in-class oral KRASG12D selective inhibitor for clinical evaluation. KRASG12D mutations impact approximately 180,000 patients in the US and Europe, representing approximately a 2.5-fold increase in prevalence compared to KRASG12C mutations. No targeted oncology treatment options currently exist for these patients. MRTX1133 is a highly potent investigational inhibitor of the KRASG12D driver mutation and demonstrated selective and reversible inhibition of KRASG12D in both its active and inactive states. In addition, MRTX1133 administration resulted in marked tumor response in preclinical KRASG12D mutated pancreatic cancer models as well as lung and colorectal cancer models. MRTX1133 has demonstrated favorable properties including a low risk for off-target activity and drug interactions and a predicted human half-life of greater than 50 hours. "The clearance by the FDA to initiate clinical evaluation of MRTX1133, the third program in our KRAS franchise to enter clinical development, is illustrative of the innovative approach to drug discovery and demonstrates the best-in-class capabilities of the Mirati team. This particular mutation has been difficult to target, and we are confident in our novel oral formulation strategy, which we believe will enable near-complete target inhibition over the full dosing interval," said James Christensen, Ph.D. chief scientific officer, Mirati Therapeutics, Inc. "We are thrilled to advance MRTX1133 into clinical development and the potential to positively impact people living with KRASG12D-mutated cancers."